US equities
|
NVDA
$233.95
▲+1.34%
MU
$1,074.89
▼-2.05%
TSLA
$370.59
▲+4.65%
SPCX
$158.96
▲+7.35%
SNDK
$1,719.99
▼-3.79%
AMD
$633.91
▲+2.95%
STX
$848.99
▼-10.21%
INTC
$119.33
▼-0.56%
NVDA
$233.95
▲+1.34%
MU
$1,074.89
▼-2.05%
TSLA
$370.59
▲+4.65%
SPCX
$158.96
▲+7.35%
SNDK
$1,719.99
▼-3.79%
AMD
$633.91
▲+2.95%
STX
$848.99
▼-10.21%
INTC
$119.33
▼-0.56%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
Timber Pharmaceuticals Inc
(NY:
TMBR
)
N/A
UNCHANGED
Last Price
Updated: 8:00 PM EST, Nov 28, 2023
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Timber Pharmaceuticals Inc
< Previous
1
2
Next >
Timber Pharmaceuticals Receives Court Approval of All First Day Motions to Support Business Operations & Discloses Communication From NYSE American
November 28, 2023
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
Timber Pharmaceuticals Announces NYSE Acceptance of Plan to Regain Listing Compliance
September 18, 2023
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
TIMBER PHARMACEUTICALS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Timber Pharmaceuticals, Inc. - TMBR
August 29, 2023
From
Kahn Swick & Foti, LLC
Via
Business Wire
TMBR Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Timber Pharmaceuticals, Inc. Is Fair to Shareholders
August 21, 2023
From
Halper Sadeh LLC
Via
Business Wire
Timber Pharmaceuticals to be Acquired by LEO Pharma
August 21, 2023
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
Timber Pharmaceuticals Discloses Communication From NYSE American
July 03, 2023
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
Timber Pharmaceuticals to Present Interim Analyses from Phase 3 ASCEND Study of TMB-001 in Congenital Ichthyosis
June 20, 2023
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
Timber Pharmaceuticals’ (NYSE American: TMBR) Phase 3 ASCEND Study for TMB-001: A Leap Forward in Congenital Ichthyosis Treatment
June 05, 2023
Significant Progress in Timber Pharmaceuticals' Phase 3 ASCEND Study Timber Pharmaceuticals (NYSE American: TMBR), a clinical-stage biopharmaceutical company specializing in
Via
Spotlight Growth
Timber Pharmaceuticals Announces FDA Grant of CARC Waiver for TMB-001
June 05, 2023
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
Timber Pharmaceuticals Provides Business Update and Announces First Quarter 2023 Financial Results
May 15, 2023
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
Timber Pharmaceuticals Provides Business Update and Announces Fourth Quarter and Year End 2022 Financial Results
March 31, 2023
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
Timber Pharmaceuticals Announces Publication of Sub-Analysis of Phase 2b CONTROL study in Clinical and Experimental Dermatology
March 20, 2023
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
Timber Pharmaceuticals (NYSE American: TMBR) Granted Orphan Drug Designation in Europe for TMB-001
February 24, 2023
Timber Pharmaceuticals, Inc. (NYSE American: TMBR) is engaged as a clinical-stage biopharmaceutical company, which is focused on the development and
Via
Spotlight Growth
Timber Pharmaceuticals Receives European Orphan Drug Designation for TMB-001 in X-Linked Recessive Ichthyosis
February 24, 2023
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
Timber Pharmaceuticals to Host Investor Business Briefing: Milestone Achievements and Forward Outlook
December 14, 2022
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
Timber Pharmaceuticals Regains Compliance with NYSE American Continued Listing Standards
December 09, 2022
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
Timber Pharmaceuticals Provides Business Update and Announces Third Quarter 2022 Financial Results
November 14, 2022
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
Timber Pharmaceuticals, Inc. Announces 1-for-50 Reverse Stock Split
November 08, 2022
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
Timber Pharmaceuticals Announces Halt of Common Stock Trading
November 03, 2022
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
Timber Pharmaceuticals Receives European Orphan Designation for Autosomal Recessive Congenital Ichthyosis & Positive Comments on Pediatric Investigation Plan for TMB-001 in Autosomal Recessive CI & X-Linked Recessive Ichthyosis
October 25, 2022
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
Timber Pharmaceuticals Announces $1.3 Million Registered Direct Offering
October 03, 2022
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
Timber Pharmaceuticals Receives Positive Opinion on Orphan Designation from European Medicines Agency for TMB-001 for Treatment of Autosomal Recessive Congenital Ichthyosis
September 14, 2022
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
Timber Pharmaceuticals Announces Notification of NYSE American Continued Listing Deficiency
August 29, 2022
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
Timber Pharmaceuticals to Highlight Phase 2b CONTROL Study Results in Multiple Presentations at 31st EADV Congress
August 29, 2022
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
Timber Pharmaceuticals Announces Publication of Results from Phase 2b CONTROL Study of FDA-Designated Breakthrough Therapy TMB-001 in the Journal of the American Academy of Dermatology
August 26, 2022
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
Timber Pharmaceuticals Provides Business Update and Announces Second Quarter 2022 Financial Results
August 11, 2022
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
Timber Pharmaceuticals Announces Closing of $8.0 Million Public Offering
August 08, 2022
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
Timber Pharmaceuticals Announces Pricing of $8.0 Million Public Offering
August 04, 2022
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
Timber Pharmaceuticals Announces First Patients Enrolled in Phase 3 ASCEND Clinical Trial Evaluating TMB-001 in Congenital Ichthyosis
June 23, 2022
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
Timber Pharmaceuticals Receives FDA Breakthrough Therapy Designation for TMB-001 for the Treatment of Congenital Ichthyosis
May 31, 2022
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
< Previous
1
2
Next >
